Company intelligence / Profile preview
ImmVue Therapeutics
- Ownership
- Private
- Development stage
- Other
01
Overview
ImmVue Therapeutics has developed a novel approach to immunotherapy by targeting intracellular kinases such as ITK and BTK to enhance T and B cell function. Their programs are in the pre-clinical stage, leveraging both proprietary allosteric chemistry and advanced AI-driven drug discovery platforms. No clinical results have been published yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesAllosteric modulators (intracellular kinase modulation)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Variational AI (collaboration on generative AI-driven small molecule lead generation for immuno-oncology targets)
Beyond the preview
Go deeper on ImmVue Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmVue Therapeutics.